CWM
VTYX

CIBC World Markets’s Ventyx Biosciences VTYX Stock Holding History

CIBC World Markets’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,485
Closed -$15.5K – 1952
2025
Q1 		$15.5K Buy
+13,485
New +$23.2K ﹤0.01% 1808

Other funds holding VTYX

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

CIBC World Markets's VTYX Position: Q2 2025 in Review

CIBC World Markets sold out of Ventyx Biosciences (VTYX) in Q2 2025, closing a stake of 13,485 shares — an estimated $15.5K sold.

CIBC World Markets first reported a position in VTYX in Q1 2025 and held it in 1 quarter. The position peaked at $15.5K in Q1 2025. 114 funds tracked by Wall St. Rank hold VTYX as of Q2 2025.

  • CIBC World Markets reported no remaining Ventyx Biosciences position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 13,485 Ventyx Biosciences shares in Q2 2025, an estimated $15.5K.
  • CIBC World Markets first reported a position in Ventyx Biosciences in Q1 2025 and held it in 1 quarter.
  • CIBC World Markets's Ventyx Biosciences position peaked at $15.5K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.